On April 6 2017 the General Court rendered its judgment in NIMORAL (Case T-49/16). The case concerned an application by Azanta A/S for the trademark NIMORAL in relation to pharmaceutical preparations for enhancing the effect of radiotherapy on cancer patients in Class 5. The application was opposed by Novartis AG on the basis of the earlier EU trademark NEORAL, also registered in Class 5 in relation to pharmaceutical preparations.

This legal update is part of World Trademark Review's premium intelligence and is only available to subscribers.

Register to access two of our subscriber only articles per month

Subscribe for unlimited access to articles, in-depth analysis and research from the World Trademark Review experts

Already registered? Log in

What our customers are saying

"There is no doubt that World Trademark Review is an important tool for people dealing with trademark matters"

Maria de Lourdes Lopes Dias
Senior Partner
Lopes Dias & Associados


Subscribe to World Trademark Review to receive access to the full range of trademark intelligence, insight, and case law, as well as our guides, rankings and daily market insight delivered to your inbox.

Why subscribe?

Share this article